NCT07087860 - Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 7, 2028

Study Completion Date

August 7, 2028

Conditions

Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRefractory Bladder Urothelial CarcinomaRefractory Renal Pelvis and Ureter Urothelial CarcinomaStage IV Bladder Cancer AJCC v7Stage IV Renal Pelvis and Ureter Cancer AJCC v7

Interventions

OTHER

Best Practice

Receive standard of care

PROCEDURE

Biospecimen Collection

Undergo collection of blood and urine samples

PROCEDURE

Central Venous Cannula Insertion

Undergo central line placement

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

DRUG

Enfortumab Vedotin

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Plasmapheresis

Undergo TPE

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester